デフォルト表紙
市場調査レポート
商品コード
1455604

精神科/抑うつ向け薬理遺伝学検査の世界市場

Global Pharmacogenetics Testing in PsychiatryDepression Market

出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 565 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.16円
精神科/抑うつ向け薬理遺伝学検査の世界市場
出版日: 2024年02月01日
発行: Data Bridge Market Research
ページ情報: 英文 565 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の精神科/抑うつ向け薬理遺伝学検査の市場規模は、2023年の12億2,447万3,840米ドルから2031年までに26億6,438万2,700米ドルに達し、2024年~2034年の予測期間にCAGRで10.4%の成長が見込まれます。

当レポートでは、世界の精神科/抑うつ向け薬理遺伝学検査市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTAL分析
  • ポーターのファイブフォース分析

第5章 産業の考察

第6章 世界の精神科/抑うつ向け薬理遺伝学検査市場、規制

  • 米国
  • 欧州連合(EU)
  • フランス
  • オーストラリア
  • 韓国

第7章 市場の概要

  • 促進要因
    • 抑うつの患者人口の増加
    • 遺伝的変異性に起因するメーカーによる取り組み
    • 医療支出の増加とバイオ技術部門の成長
    • 個別化医療と精密医療への関心の高まり
  • 抑制要因
    • 不十分な臨床評価
    • メンタルヘルスに対する偏見と認識
    • 償還の不足
  • 機会
    • 遺伝子検査の進歩
    • 新興スタートアップのイノベーション
    • コスト節減策の実施による医療費の削減
  • 課題
    • データプライバシーとセキュリティに関する懸念の高まり
    • 熟練した医療従事者の不足

第8章 世界の精神科/抑うつ向け薬理遺伝学検査市場:製品別

  • 概要
  • 消耗品
  • 機器
  • ソフトウェア、サービス

第9章 世界の精神科/抑うつ向け薬理遺伝学検査市場:検査タイプ別

  • 概要
  • 全ゲノムシーケンシング
  • 染色体アレイベースの検査

第10章 世界の精神科/抑うつ向け薬理遺伝学検査市場:タイプ別

  • 概要
  • 不安
  • 抑うつ
  • 気分障害
  • 双極性障害
  • 摂食障害
  • 精神障害

第11章 世界の精神科/抑うつ向け薬理遺伝学検査市場:遺伝子タイプ別

  • 概要
  • CYP2C19
  • CYP2C9、VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
  • その他

第12章 世界の精神科/抑うつ向け薬理遺伝学検査市場:患者タイプ別

  • 概要
  • 成人
  • 高齢者
  • 子供

第13章 世界の精神科/抑うつ向け薬理遺伝学検査市場:エンドユーザー別

  • 概要
  • 病院、診療所
  • 診断検査室
  • 学術、研究機関
  • その他

第14章 世界の精神科/抑うつ向け薬理遺伝学検査市場:流通チャネル別

  • 概要
  • 直接提供
  • 第三者流通
  • 病院薬局
  • その他

第15章 世界の精神科/抑うつ向け薬理遺伝学検査市場の動向:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • スペイン
    • トルコ
    • オランダ
    • スイス
    • ポーランド
    • ハンガリー
    • オーストリア
    • ノルウェー
    • アイルランド
    • リトアニア
    • その他の欧州
  • アジア太平洋
    • 日本
    • 中国
    • 韓国
    • インド
    • オーストラリア
    • シンガポール
    • タイ
    • マレーシア
    • インドネシア
    • フィリピン
    • ベトナム
    • その他のアジア太平洋
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • エジプト
    • その他の中東・アフリカ
  • 南米
    • ブラジル
    • アルゼンチン
    • ペルー
    • その他の南米

第16章 世界の精神科/抑うつ向け薬理遺伝学検査市場:企業情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋

第17章 SWOT分析

第18章 企業プロファイル

  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • SONIC HEALTHCARE LIMITED
  • QIAGEN
  • AB-BIOTICS, S.A.
  • BIOGENIQ INC.
  • CASTLE BIOSCIENCE, INC.
  • CORIELL LIFE SCIENCES
  • DYNAMIC DNA LABORATORIES
  • EUROFINS SCIENTIFIC
  • GENELEX (SUBSIADIARY OF INVITAE CORPORATION.)
  • GENEWIZ (PART OF AZENTA LIFE SCIENCES)
  • GENOMIND, INC.
  • GENXYS
  • HEALTHSPEK
  • HUDSONALPHA
  • MD LABS
  • ONEOME, LLC
  • PACBIO

第19章 アンケート

第20章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 110
  • TABLE 2 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 110
  • TABLE 3 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 111
  • TABLE 4 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 112
  • TABLE 5 GLOBAL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 112
  • TABLE 6 GLOBAL INSTRUMENTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 113
  • TABLE 7 GLOBAL SOFTWARE AND SERVICES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
  • TABLE 8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 119
  • TABLE 9 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 119
  • TABLE 10 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 120
  • TABLE 11 GLOBAL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 121
  • TABLE 12 GLOBAL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 121
  • TABLE 13 GLOBAL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 122
  • TABLE 14 GLOBAL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 122
  • TABLE 15 GLOBAL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 123
  • TABLE 16 GLOBAL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 123
  • TABLE 17 GLOBAL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 124
  • TABLE 18 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 129
  • TABLE 19 GLOBAL ANXIETY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 130
  • TABLE 20 GLOBAL DEPRESSION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 131
  • TABLE 21 GLOBAL MOOD DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 132
  • TABLE 22 GLOBAL BIPOLAR DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 133
  • TABLE 23 GLOBAL EATING DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 134
  • TABLE 24 GLOBAL PSYCHOTIC DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 135
  • TABLE 25 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 140
  • TABLE 26 GLOBAL CYP2C19 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 141
  • TABLE 27 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 142
  • TABLE 28 GLOBAL CYP2D6 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 143
  • TABLE 29 GLOBAL HLA-B IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 144
  • TABLE 30 GLOBAL HTR2A/C IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 145
  • TABLE 31 GLOBAL HLA-A IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 146
  • TABLE 32 GLOBAL CYP3A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 147
  • TABLE 33 GLOBAL SLC6A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 148
  • TABLE 34 GLOBAL MTHFR IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 149
  • TABLE 35 GLOBAL COMT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 150
  • TABLE 36 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 151
  • TABLE 37 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 156
  • TABLE 38 GLOBAL ADULT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 157
  • TABLE 39 GLOBAL GERIATRIC IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 158
  • TABLE 40 GLOBAL CHILD IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 159
  • TABLE 41 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 164
  • TABLE 42 GLOBAL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 165
  • TABLE 43 GLOBAL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 165
  • TABLE 44 GLOBAL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 166
  • TABLE 45 GLOBAL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 166
  • TABLE 46 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 167
  • TABLE 47 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 167
  • TABLE 48 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 168
  • TABLE 49 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 173
  • TABLE 50 GLOBAL DIRECT TENDER IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 174
  • TABLE 51 GLOBAL THIRD PARTY DISTRIBUTION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 175
  • TABLE 52 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 176
  • TABLE 53 GLOBAL OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 177
  • TABLE 54 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2022-2031 (USD THOUSAND) 182
  • TABLE 55 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 183
  • TABLE 56 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 183
  • TABLE 57 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 183
  • TABLE 58 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 184
  • TABLE 59 NORTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 184
  • TABLE 60 NORTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 184
  • TABLE 61 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 184
  • TABLE 62 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 185
  • TABLE 63 NORTH AMERICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 185
  • TABLE 64 NORTH AMERICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 185
  • TABLE 65 NORTH AMERICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 186
  • TABLE 66 NORTH AMERICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 186
  • TABLE 67 NORTH AMERICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 186
  • TABLE 68 NORTH AMERICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 187
  • TABLE 69 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 187
  • TABLE 70 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 187
  • TABLE 71 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
  • TABLE 72 NORTH AMERICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
  • TABLE 73 NORTH AMERICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
  • TABLE 74 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
  • TABLE 75 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 189
  • TABLE 76 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 190
  • TABLE 77 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 190
  • TABLE 78 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 190
  • TABLE 79 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 190
  • TABLE 80 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 191
  • TABLE 81 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 191
  • TABLE 82 U.S. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 191
  • TABLE 83 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 191
  • TABLE 84 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 192
  • TABLE 85 U.S. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 192
  • TABLE 86 U.S. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 192
  • TABLE 87 U.S. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 193
  • TABLE 88 U.S. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 193
  • TABLE 89 U.S. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 193
  • TABLE 90 U.S. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 194
  • TABLE 91 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 194
  • TABLE 92 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 194
  • TABLE 93 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 195
  • TABLE 94 U.S. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 195
  • TABLE 95 U.S. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 195
  • TABLE 96 U.S. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 195
  • TABLE 97 U.S. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 196
  • TABLE 98 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 197
  • TABLE 99 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 197
  • TABLE 100 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 197
  • TABLE 101 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 197
  • TABLE 102 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 198
  • TABLE 103 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 198
  • TABLE 104 CANADA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 198
  • TABLE 105 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 198
  • TABLE 106 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 199
  • TABLE 107 CANADA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 199
  • TABLE 108 CANADA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 199
  • TABLE 109 CANADA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 200
  • TABLE 110 CANADA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 200
  • TABLE 111 CANADA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 200
  • TABLE 112 CANADA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 201
  • TABLE 113 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 201
  • TABLE 114 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 201
  • TABLE 115 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 202
  • TABLE 116 CANADA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 202
  • TABLE 117 CANADA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 202
  • TABLE 118 CANADA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 202
  • TABLE 119 CANADA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 203
  • TABLE 120 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 204
  • TABLE 121 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 204
  • TABLE 122 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 204
  • TABLE 123 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 204
  • TABLE 124 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 205
  • TABLE 125 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 205
  • TABLE 126 MEXICO CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 205
  • TABLE 127 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 205
  • TABLE 128 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 206
  • TABLE 129 MEXICO EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 206
  • TABLE 130 MEXICO KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 206
  • TABLE 131 MEXICO LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 207
  • TABLE 132 MEXICO DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 207
  • TABLE 133 MEXICO MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 207
  • TABLE 134 MEXICO CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 208
  • TABLE 135 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 208
  • TABLE 136 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 208
  • TABLE 137 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 209
  • TABLE 138 MEXICO HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 209
  • TABLE 139 MEXICO DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 209
  • TABLE 140 MEXICO ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 209
  • TABLE 141 MEXICO PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 210
  • TABLE 142 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 211
  • TABLE 143 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 212
  • TABLE 144 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 212
  • TABLE 145 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 212
  • TABLE 146 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 213
  • TABLE 147 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 213
  • TABLE 148 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 213
  • TABLE 149 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 214
  • TABLE 150 EUROPE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 214
  • TABLE 151 EUROPE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 215
  • TABLE 152 EUROPE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 215
  • TABLE 153 EUROPE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 216
  • TABLE 154 EUROPE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 216
  • TABLE 155 EUROPE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 216
  • TABLE 156 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 217
  • TABLE 157 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 217
  • TABLE 158 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 218
  • TABLE 159 EUROPE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 218
  • TABLE 160 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 218
  • TABLE 161 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 219
  • TABLE 162 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 219
  • TABLE 163 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 220
  • TABLE 164 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 220
  • TABLE 165 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 220
  • TABLE 166 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 221
  • TABLE 167 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 221
  • TABLE 168 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 221
  • TABLE 169 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 221
  • TABLE 170 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 221
  • TABLE 171 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 222
  • TABLE 172 GERMANY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 222
  • TABLE 173 GERMANY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 223
  • TABLE 174 GERMANY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 223
  • TABLE 175 GERMANY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 224
  • TABLE 176 GERMANY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 224
  • TABLE 177 GERMANY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 224
  • TABLE 178 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 225
  • TABLE 179 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 225
  • TABLE 180 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 226
  • TABLE 181 GERMANY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 226
  • TABLE 182 GERMANY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 226
  • TABLE 183 GERMANY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 227
  • TABLE 184 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 227
  • TABLE 185 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 228
  • TABLE 186 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 228
  • TABLE 187 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 228
  • TABLE 188 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 228
  • TABLE 189 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 229
  • TABLE 190 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 229
  • TABLE 191 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 229
  • TABLE 192 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 229
  • TABLE 193 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 230
  • TABLE 194 FRANCE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 230
  • TABLE 195 FRANCE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 231
  • TABLE 196 FRANCE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 231
  • TABLE 197 FRANCE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 232
  • TABLE 198 FRANCE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 232
  • TABLE 199 FRANCE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 232
  • TABLE 200 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 233
  • TABLE 201 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 233
  • TABLE 202 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 234
  • TABLE 203 FRANCE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 234
  • TABLE 204 FRANCE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 234
  • TABLE 205 FRANCE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 235
  • TABLE 206 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 235
  • TABLE 207 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 236
  • TABLE 208 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 236
  • TABLE 209 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 236
  • TABLE 210 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 236
  • TABLE 211 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 237
  • TABLE 212 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 237
  • TABLE 213 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 237
  • TABLE 214 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 237
  • TABLE 215 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 238
  • TABLE 216 U.K. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 238
  • TABLE 217 U.K. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 239
  • TABLE 218 U.K. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 239
  • TABLE 219 U.K. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 240
  • TABLE 220 U.K. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 240
  • TABLE 221 U.K. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 240
  • TABLE 222 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 241
  • TABLE 223 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 241
  • TABLE 224 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 242
  • TABLE 225 U.K. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 242
  • TABLE 226 U.K. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 242
  • TABLE 227 U.K. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 243
  • TABLE 228 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 243
  • TABLE 229 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 244
  • TABLE 230 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 244
  • TABLE 231 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 244
  • TABLE 232 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 244
  • TABLE 233 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 245
  • TABLE 234 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 245
  • TABLE 235 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 245
  • TABLE 236 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 245
  • TABLE 237 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 246
  • TABLE 238 ITALY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 246
  • TABLE 239 ITALY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 247
  • TABLE 240 ITALY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 247
  • TABLE 241 ITALY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 248
  • TABLE 242 ITALY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 248
  • TABLE 243 ITALY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 248
  • TABLE 244 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 249
  • TABLE 245 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 249
  • TABLE 246 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 250
  • TABLE 247 ITALY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 250
  • TABLE 248 ITALY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 250
  • TABLE 249 ITALY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 251
  • TABLE 250 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 251
  • TABLE 251 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 252
  • TABLE 252 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 252
  • TABLE 253 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 252
  • TABLE 254 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 252
  • TABLE 255 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 253
  • TABLE 256 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 253
  • TABLE 257 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 253
  • TABLE 258 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 253
  • TABLE 259 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 254
  • TABLE 260 RUSSIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 254
  • TABLE 261 RUSSIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 255
  • TABLE 262 RUSSIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 255
  • TABLE 263 RUSSIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 256
  • TABLE 264 RUSSIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 256
  • TABLE 265 RUSSIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 256
  • TABLE 266 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 257
  • TABLE 267 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 257
  • TABLE 268 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 258
  • TABLE 269 RUSSIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 258
  • TABLE 270 RUSSIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 258
  • TABLE 271 RUSSIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 259
  • TABLE 272 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 259
  • TABLE 273 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 260
  • TABLE 274 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 260
  • TABLE 275 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 260
  • TABLE 276 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 260
  • TABLE 277 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 261
  • TABLE 278 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 261
  • TABLE 279 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 261
  • TABLE 280 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 261
  • TABLE 281 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 262
  • TABLE 282 SPAIN EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 262
  • TABLE 283 SPAIN KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 263
  • TABLE 284 SPAIN LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 263
  • TABLE 285 SPAIN DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 264
  • TABLE 286 SPAIN MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 264
  • TABLE 287 SPAIN CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 264
  • TABLE 288 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 265
  • TABLE 289 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 265
  • TABLE 290 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 266
  • TABLE 291 SPAIN HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 266
  • TABLE 292 SPAIN DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 266
  • TABLE 293 SPAIN ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 267
  • TABLE 294 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 267
  • TABLE 295 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 268
  • TABLE 296 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 268
  • TABLE 297 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 268
  • TABLE 298 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 268
  • TABLE 299 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 269
  • TABLE 300 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 269
  • TABLE 301 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 269
  • TABLE 302 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 269
  • TABLE 303 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 270
  • TABLE 304 TURKEY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 270
  • TABLE 305 TURKEY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 271
  • TABLE 306 TURKEY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 271
  • TABLE 307 TURKEY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 272
  • TABLE 308 TURKEY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 272
  • TABLE 309 TURKEY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 272
  • TABLE 310 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 273
  • TABLE 311 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 273
  • TABLE 312 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 274
  • TABLE 313 TURKEY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 274
  • TABLE 314 TURKEY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 274
  • TABLE 315 TURKEY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 275
  • TABLE 316 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 275
  • TABLE 317 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 276
  • TABLE 318 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 276
  • TABLE 319 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 276
  • TABLE 320 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 276
  • TABLE 321 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 277
  • TABLE 322 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 277
  • TABLE 323 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 277
  • TABLE 324 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 277
  • TABLE 325 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 278
  • TABLE 326 NETHERLANDS EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 278
  • TABLE 327 NETHERLANDS KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 279
  • TABLE 328 NETHERLANDS LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 279
  • TABLE 329 NETHERLANDS DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 280
  • TABLE 330 NETHERLANDS MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 280
  • TABLE 331 NETHERLANDS CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 280
  • TABLE 332 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 281
  • TABLE 333 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 281
  • TABLE 334 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 282
  • TABLE 335 NETHERLANDS HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 282
  • TABLE 336 NETHERLANDS DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 282
  • TABLE 337 NETHERLANDS ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 283
  • TABLE 338 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 283
  • TABLE 339 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 284
  • TABLE 340 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 284
  • TABLE 341 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 284
  • TABLE 342 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 284
  • TABLE 343 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 285
  • TABLE 344 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 285
  • TABLE 345 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 285
  • TABLE 346 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 285
  • TABLE 347 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 286
  • TABLE 348 SWITZERLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 286
  • TABLE 349 SWITZERLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 287
  • TABLE 350 SWITZERLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 287
  • TABLE 351 SWITZERLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 288
  • TABLE 352 SWITZERLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 288
  • TABLE 353 SWITZERLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 288
  • TABLE 354 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 289
  • TABLE 355 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 289
  • TABLE 356 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 290
  • TABLE 357 SWITZERLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 290
  • TABLE 358 SWITZERLAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 290
  • TABLE 359 SWITZERLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 291
  • TABLE 360 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 291
  • TABLE 361 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 292
  • TABLE 362 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 292
  • TABLE 363 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 292
  • TABLE 364 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 292
  • TABLE 365 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 293
  • TABLE 366 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 293
  • TABLE 367 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 293
  • TABLE 368 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 293
  • TABLE 369 POLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 294
  • TABLE 370 POLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 294
  • TABLE 371 POLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 295
  • TABLE 372 POLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 295
  • TABLE 373 POLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 296
  • TABLE 374 POLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 296
  • TABLE 375 POLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 296
  • TABLE 376 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 297
  • TABLE 377 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 297
  • TABLE 378 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 298
  • TABLE 379 POLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 298
  • TABLE 380 POLAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 298
  • TABLE 381 POLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 299
  • TABLE 382 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 299
  • TABLE 383 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 300
  • TABLE 384 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 300
  • TABLE 385 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 300
  • TABLE 386 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 300
  • TABLE 387 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 301
  • TABLE 388 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 301
  • TABLE 389 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 301
  • TABLE 390 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 301
  • TABLE 391 HUNGARY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 302
  • TABLE 392 HUNGARY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 302
  • TABLE 393 HUNGARY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 303
  • TABLE 394 HUNGARY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 303
  • TABLE 395 HUNGARY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 304
  • TABLE 396 HUNGARY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 304
  • TABLE 397 HUNGARY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 304
  • TABLE 398 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 305
  • TABLE 399 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 305
  • TABLE 400 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 306
  • TABLE 401 HUNGARY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 306
  • TABLE 402 HUNGARY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 306
  • TABLE 403 HUNGARY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 307
  • TABLE 404 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 307
  • TABLE 405 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 308
  • TABLE 406 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 308
  • TABLE 407 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 308
  • TABLE 408 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 308
  • TABLE 409 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 309
  • TABLE 410 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 309
  • TABLE 411 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 309
  • TABLE 412 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 309
  • TABLE 413 AUSTRIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 310
  • TABLE 414 AUSTRIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 310
  • TABLE 415 AUSTRIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 311
  • TABLE 416 AUSTRIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 311
  • TABLE 417 AUSTRIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 312
  • TABLE 418 AUSTRIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 312
  • TABLE 419 AUSTRIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 312
  • TABLE 420 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 313
  • TABLE 421 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 313
  • TABLE 422 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 314
  • TABLE 423 AUSTRIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 314
  • TABLE 424 AUSTRIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 314
  • TABLE 425 AUSTRIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 315
  • TABLE 426 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 315
  • TABLE 427 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 316
  • TABLE 428 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 316
  • TABLE 429 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 316
  • TABLE 430 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 316
  • TABLE 431 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 317
  • TABLE 432 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 317
  • TABLE 433 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 317
  • TABLE 434 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 317
  • TABLE 435 NORWAY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 318
  • TABLE 436 NORWAY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 318
  • TABLE 437 NORWAY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 319
  • TABLE 438 NORWAY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 319
  • TABLE 439 NORWAY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 320
  • TABLE 440 NORWAY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 320
  • TABLE 441 NORWAY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 321
  • TABLE 442 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 321
  • TABLE 443 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 322
  • TABLE 444 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 322
  • TABLE 445 NORWAY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 322
  • TABLE 446 NORWAY DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 323
  • TABLE 447 NORWAY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 323
  • TABLE 448 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 323
  • TABLE 449 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 324
  • TABLE 450 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 324
  • TABLE 451 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 324
  • TABLE 452 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 324
  • TABLE 453 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 325
  • TABLE 454 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 325
  • TABLE 455 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 325
  • TABLE 456 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 325
  • TABLE 457 IRELAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 326
  • TABLE 458 IRELAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 326
  • TABLE 459 IRELAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 327
  • TABLE 460 IRELAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 327
  • TABLE 461 IRELAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 328
  • TABLE 462 IRELAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 328
  • TABLE 463 IRELAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 328
  • TABLE 464 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 329
  • TABLE 465 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 329
  • TABLE 466 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 330
  • TABLE 467 IRELAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 330
  • TABLE 468 IRELAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 330
  • TABLE 469 IRELAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 331
  • TABLE 470 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 331
  • TABLE 471 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 332
  • TABLE 472 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 332
  • TABLE 473 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 332
  • TABLE 474 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 332
  • TABLE 475 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 333
  • TABLE 476 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 333
  • TABLE 477 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 333
  • TABLE 478 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 333
  • TABLE 479 LITHUANIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 334
  • TABLE 480 LITHUANIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 334
  • TABLE 481 LITHUANIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 335
  • TABLE 482 LITHUANIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 335
  • TABLE 483 LITHUANIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 336
  • TABLE 484 LITHUANIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 336
  • TABLE 485 LITHUANIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 336
  • TABLE 486 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 337
  • TABLE 487 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 337
  • TABLE 488 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 338
  • TABLE 489 LITHUANIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 338
  • TABLE 490 LITHUANIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 338
  • TABLE 491 LITHUANIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 339
  • TABLE 492 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 339
  • TABLE 493 REST OF EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 340
  • TABLE 494 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 341
  • TABLE 495 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 341
  • TABLE 496 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 341
  • TABLE 497 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 342
  • TABLE 498 ASIA-PACIFIC CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 342
  • TABLE 499 ASIA-PACIFIC CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 342
  • TABLE 500 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 343
  • TABLE 501 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 343
  • TABLE 502 ASIA-PACIFIC EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 343
  • TABLE 503 ASIA-PACIFIC KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 344
  • TABLE 504 ASIA-PACIFIC LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 344
  • TABLE 505 ASIA-PACIFIC DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 344
  • TABLE 506 ASIA-PACIFIC MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 345
  • TABLE 507 ASIA-PACIFIC CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 345
  • TABLE 508 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 345
  • TABLE 509 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 346
  • TABLE 510 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 346
  • TABLE 511 ASIA-PACIFIC HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 346
  • TABLE 512 ASIA-PACIFIC DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 347
  • TABLE 513 ASIA-PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 347
  • TABLE 514 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 347
  • TABLE 515 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 348
  • TABLE 516 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 348
  • TABLE 517 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 348
  • TABLE 518 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 349
  • TABLE 519 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 349
  • TABLE 520 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 349
  • TABLE 521 JAPAN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 349
  • TABLE 522 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 349
  • TABLE 523 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 350
  • TABLE 524 JAPAN EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 350
  • TABLE 525 JAPAN DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 351
  • TABLE 526 JAPAN MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 351
  • TABLE 527 JAPAN CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 351
  • TABLE 528 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 351
  • TABLE 529 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 352
  • TABLE 530 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 353
  • TABLE 531 JAPAN HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 353
  • TABLE 532 JAPAN DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 353
  • TABLE 533 JAPAN ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 354
  • TABLE 534 JAPAN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 354
  • TABLE 535 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 355
  • TABLE 536 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 355
  • TABLE 537 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 355
  • TABLE 538 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 356
  • TABLE 539 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 356
  • TABLE 540 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 356
  • TABLE 541 CHINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 356
  • TABLE 542 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 356
  • TABLE 543 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 357
  • TABLE 544 CHINA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 357
  • TABLE 545 CHINA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 358
  • TABLE 546 CHINA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 358
  • TABLE 547 CHINA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 359
  • TABLE 548 CHINA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 359
  • TABLE 549 CHINA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 359
  • TABLE 550 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 359
  • TABLE 551 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 360
  • TABLE 552 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 361
  • TABLE 553 CHINA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 361
  • TABLE 554 CHINA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 361
  • TABLE 555 CHINA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 362
  • TABLE 556 CHINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 362
  • TABLE 557 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 363
  • TABLE 558 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 363
  • TABLE 559 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 363
  • TABLE 560 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 364
  • TABLE 561 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 364
  • TABLE 562 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 364
  • TABLE 563 SOUTH KOREA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 364
  • TABLE 564 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 364
  • TABLE 565 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 365
  • TABLE 566 SOUTH KOREA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 365
  • TABLE 567 SOUTH KOREA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 366
  • TABLE 568 SOUTH KOREA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 366
  • TABLE 569 SOUTH KOREA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 367
  • TABLE 570 SOUTH KOREA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 367
  • TABLE 571 SOUTH KOREA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 367
  • TABLE 572 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 367
  • TABLE 573 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 368
  • TABLE 574 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 369
  • TABLE 575 SOUTH KOREA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 369
  • TABLE 576 SOUTH KOREA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 369
  • TABLE 577 SOUTH KOREA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 370
  • TABLE 578 SOUTH KOREA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 370
  • TABLE 579 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 371
  • TABLE 580 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 371
  • TABLE 581 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 371
  • TABLE 582 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 372
  • TABLE 583 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 372
  • TABLE 584 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 372
  • TABLE 585 INDIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 372
  • TABLE 586 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 372
  • TABLE 587 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 373
  • TABLE 588 INDIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 373
  • TABLE 589 INDIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 374
  • TABLE 590 INDIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 374
  • TABLE 591 INDIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 375
  • TABLE 592 INDIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 375
  • TABLE 593 INDIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 375
  • TABLE 594 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 375
  • TABLE 595 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 376
  • TABLE 596 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 377
  • TABLE 597 INDIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 377
  • TABLE 598 INDIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 377
  • TABLE 599 INDIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 378
  • TABLE 600 INDIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 378
  • TABLE 601 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 379
  • TABLE 602 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 379
  • TABLE 603 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 379
  • TABLE 604 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 380
  • TABLE 605 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 380
  • TABLE 606 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 380
  • TABLE 607 AUSTRALIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 380
  • TABLE 608 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 380
  • TABLE 609 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 380
  • TABLE 610 AUSTRALIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 381
  • TABLE 611 AUSTRALIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 382
  • TABLE 612 AUSTRALIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 382
  • TABLE 613 AUSTRALIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 383
  • TABLE 614 AUSTRALIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 383
  • TABLE 615 AUSTRALIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 383
  • TABLE 616 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 383
  • TABLE 617 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 384
  • TABLE 618 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 385
  • TABLE 619 AUSTRALIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 385
  • TABLE 620 AUSTRALIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 385
  • TABLE 621 AUSTRALIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 386
  • TABLE 622 AUSTRALIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 386
  • TABLE 623 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 387
  • TABLE 624 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 387
  • TABLE 625 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 387
  • TABLE 626 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 388
  • TABLE 627 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 388
  • TABLE 628 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 388
  • TABLE 629 SINGAPORE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 388
  • TABLE 630 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 388
  • TABLE 631 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 388
  • TABLE 632 SINGAPORE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 389
  • TABLE 633 SINGAPORE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 389
  • TABLE 634 SINGAPORE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 389
  • TABLE 635 SINGAPORE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 390
  • TABLE 636 SINGAPORE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 391
  • TABLE 637 SINGAPORE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 391
  • TABLE 638 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 392
  • TABLE 639 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 392
  • TABLE 640 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 393
  • TABLE 641 SINGAPORE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 393
  • TABLE 642 SINGAPORE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 393
  • TABLE 643 SINGAPORE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 394
  • TABLE 644 SINGAPORE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 394
  • TABLE 645 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 395
  • TABLE 646 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 395
  • TABLE 647 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 395
  • TABLE 648 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 396
  • TABLE 649 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 396
  • TABLE 650 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 396
  • TABLE 651 THAILAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 396
  • TABLE 652 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 396
  • TABLE 653 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 396
  • TABLE 654 THAILAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 397
  • TABLE 655 THAILAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 398
  • TABLE 656 THAILAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 398
  • TABLE 657 THAILAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 399
  • TABLE 658 THAILAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 399
  • TABLE 659 THAILAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 399
  • TABLE 660 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 400
  • TABLE 661 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 400
  • TABLE 662 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 401
  • TABLE 663 THAILAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 401
  • TABLE 664 THAILAND DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 401
  • TABLE 665 THAILAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 402
  • TABLE 666 THAILAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 402
  • TABLE 667 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 403
  • TABLE 668 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 403
  • TABLE 669 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 403
  • TABLE 670 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 404
  • TABLE 671 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 404
  • TABLE 672 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 404
  • TABLE 673 MALAYSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 404
  • TABLE 674 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 404
  • TABLE 675 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 404
  • TABLE 676 MALAYSIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 405
  • TABLE 677 MALAYSIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 406
  • TABLE 678 MALAYSIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 406
  • TABLE 679 MALAYSIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 407
  • TABLE 680 MALAYSIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 407
  • TABLE 681 MALAYSIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 407
  • TABLE 682 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 408
  • TABLE 683 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 408
  • TABLE 684 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 408
  • TABLE 685 MALAYSIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 409
  • TABLE 686 MALAYSIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 409
  • TABLE 687 MALAYSIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 409
  • TABLE 688 MALAYSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 410
  • TABLE 689 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 411
  • TABLE 690 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 411
  • TABLE 691 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 411
  • TABLE 692 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 412
  • TABLE 693 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 412
  • TABLE 694 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 412
  • TABLE 695 INDONESIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 412
  • TABLE 696 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 412
  • TABLE 697 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 412
  • TABLE 698 INDONESIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 413
  • TABLE 699 INDONESIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 414
  • TABLE 700 INDONESIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 414
  • TABLE 701 INDONESIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 415
  • TABLE 702 INDONESIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 415
  • TABLE 703 INDONESIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 415
  • TABLE 704 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 416
  • TABLE 705 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 416
  • TABLE 706 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 417
  • TABLE 707 INDONESIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 417
  • TABLE 708 INDONESIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 417
  • TABLE 709 INDONESIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 418
  • TABLE 710 INDONESIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 418
  • TABLE 711 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 419
  • TABLE 712 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 419
  • TABLE 713 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 419
  • TABLE 714 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 420
  • TABLE 715 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 420
  • TABLE 716 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 420
  • TABLE 717 PHILIPPINES CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 420
  • TABLE 718 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 420
  • TABLE 719 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 420
  • TABLE 720 PHILIPPINES EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 421
  • TABLE 721 PHILIPPINES KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 422
  • TABLE 722 PHILIPPINES LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 422
  • TABLE 723 PHILIPPINES DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 423
  • TABLE 724 PHILIPPINES MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 423
  • TABLE 725 PHILIPPINES CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 423
  • TABLE 726 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 424
  • TABLE 727 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 424
  • TABLE 728 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 425
  • TABLE 729 PHILIPPINES HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 425
  • TABLE 730 PHILIPPINES DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 425
  • TABLE 731 PHILIPPINES ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 426
  • TABLE 732 PHILIPPINES PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 426
  • TABLE 733 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 427
  • TABLE 734 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 427
  • TABLE 735 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 427
  • TABLE 736 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 427
  • TABLE 737 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 428
  • TABLE 738 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME, (UNITS) 428
  • TABLE 739 VIETNAM CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 428
  • TABLE 740 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 428
  • TABLE 741 VIETNAM WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 429
  • TABLE 742 VIETNAM EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 429
  • TABLE 743 VIETNAM KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 430
  • TABLE 744 VIETNAM LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 430
  • TABLE 745 VIETNAM DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 431
  • TABLE 746 VIETNAM MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 431
  • TABLE 747 VIETNAM CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 431
  • TABLE 748 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 432
  • TABLE 749 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 432
  • TABLE 750 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 433
  • TABLE 751 VIETNAM HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 433
  • TABLE 752 VIETNAM DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 433
  • TABLE 753 VIETNAM ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 434
  • TABLE 754 VIETNAM PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 434
  • TABLE 755 REST OF ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 435
  • TABLE 756 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 436
  • TABLE 757 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 436
  • TABLE 758 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 436
  • TABLE 759 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 437
  • TABLE 760 MIDDLE EAST AND AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 437
  • TABLE 761 MIDDLE EAST AND AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 437
  • TABLE 762 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 437
  • TABLE 763 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 438
  • TABLE 764 MIDDLE EAST AND AFRICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 438
  • TABLE 765 MIDDLE EAST AND AFRICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 438
  • TABLE 766 MIDDLE EAST AND AFRICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 439
  • TABLE 767 MIDDLE EAST AND AFRICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 439
  • TABLE 768 MIDDLE EAST AND AFRICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 439
  • TABLE 769 MIDDLE EAST AND AFRICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 440
  • TABLE 770 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 440
  • TABLE 771 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 440
  • TABLE 772 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
  • TABLE 773 MIDDLE EAST AND AFRICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
  • TABLE 774 MIDDLE EAST AND AFRICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
  • TABLE 775 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
  • TABLE 776 MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 442
  • TABLE 777 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 443
  • TABLE 778 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 443
  • TABLE 779 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 443
  • TABLE 780 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 443
  • TABLE 781 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 444
  • TABLE 782 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 444
  • TABLE 783 SOUTH AFRICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 444
  • TABLE 784 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 444
  • TABLE 785 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 445
  • TABLE 786 SOUTH AFRICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 445
  • TABLE 787 SOUTH AFRICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 445
  • TABLE 788 SOUTH AFRICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 446
  • TABLE 789 SOUTH AFRICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 446
  • TABLE 790 SOUTH AFRICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 446
  • TABLE 791 SOUTH AFRICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 447
  • TABLE 792 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 447
  • TABLE 793 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 447
  • TABLE 794 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 448
  • TABLE 795 SOUTH AFRICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 448
  • TABLE 796 SOUTH AFRICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 448
  • TABLE 797 SOUTH AFRICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 448
  • TABLE 798 SOUTH AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 449
  • TABLE 799 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 450
  • TABLE 800 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 450
  • TABLE 801 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 450
  • TABLE 802 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 450
  • TABLE 803 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 451
  • TABLE 804 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 451
  • TABLE 805 SAUDI ARABIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 451
  • TABLE 806 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 451
  • TABLE 807 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 452
  • TABLE 808 SAUDI ARABIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 452
  • TABLE 809 SAUDI ARABIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 452
  • TABLE 810 SAUDI ARABIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 453
  • TABLE 811 SAUDI ARABIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 453
  • TABLE 812 SAUDI ARABIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 453
  • TABLE 813 SAUDI ARABIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 453
  • TABLE 814 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 454
  • TABLE 815 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 454
  • TABLE 816 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 454
  • TABLE 817 SAUDI ARABIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 455
  • TABLE 818 SAUDI ARABIA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 455
  • TABLE 819 SAUDI ARABIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 455
  • TABLE 820 SAUDI ARABIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 455
  • TABLE 821 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 456
  • TABLE 822 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 456
  • TABLE 823 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 456
  • TABLE 824 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 456
  • TABLE 825 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 457
  • TABLE 826 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 457
  • TABLE 827 U.A.E. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 457
  • TABLE 828 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 457
  • TABLE 829 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 458
  • TABLE 830 U.A.E. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 458
  • TABLE 831 U.A.E. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 458
  • TABLE 832 U.A.E. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 459
  • TABLE 833 U.A.E. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 459
  • TABLE 834 U.A.E. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 459
  • TABLE 835 U.A.E. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 459
  • TABLE 836 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 460
  • TABLE 837 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 460
  • TABLE 838 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 460
  • TABLE 839 U.A.E. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 461
  • TABLE 840 U.A.E. DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 461
  • TABLE 841 U.A.E. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 461
  • TABLE 842 U.A.E. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 461
  • TABLE 843 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 462
  • TABLE 844 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 462
  • TABLE 845 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 462
  • TABLE 846 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 462
  • TABLE 847 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 463
  • TABLE 848 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 463
  • TABLE 849 ISRAEL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 463
  • TABLE 850 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 463
  • TABLE 851 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 464
  • TABLE 852 ISRAEL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 464
  • TABLE 853 ISRAEL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 464
  • TABLE 854 ISRAEL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 465
  • TABLE 855 ISRAEL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 465
  • TABLE 856 ISRAEL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 465
  • TABLE 857 ISRAEL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 465
  • TABLE 858 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 466
  • TABLE 859 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 466
  • TABLE 860 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 466
  • TABLE 861 ISRAEL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 467
  • TABLE 862 ISRAEL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 467
  • TABLE 863 ISRAEL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 467
  • TABLE 864 ISRAEL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 468
  • TABLE 865 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 469
  • TABLE 866 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 469
  • TABLE 867 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 469
  • TABLE 868 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 469
  • TABLE 869 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 470
  • TABLE 870 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 470
  • TABLE 871 EGYPT CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 470
  • TABLE 872 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 470
  • TABLE 873 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 471
  • TABLE 874 EGYPT EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 471
  • TABLE 875 EGYPT KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 471
  • TABLE 876 EGYPT LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 472
  • TABLE 877 EGYPT DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 472
  • TABLE 878 EGYPT MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 472
  • TABLE 879 EGYPT CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 473
  • TABLE 880 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2022-2031 (USD THOUSAND) 473
  • TABLE 881 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 473
  • TABLE 882 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 474
  • TABLE 883 EGYPT HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 474
  • TABLE 884 EGYPT DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 474
  • TABLE 885 EGYPT ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 475
  • TABLE 886 EGYPT PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 475
  • TABLE 887 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 476
  • TABLE 888 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 477
  • TABLE 889 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 477
  • TABLE 890 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 477
  • TABLE 891 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 478
  • TABLE 892 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 478
  • TABLE 893 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 478
  • TABLE 894 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 478
  • TABLE 895 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 479
  • TABLE 896 SOUTH AMERICA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 479
  • TABLE 897 SOUTH AMERICA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 479
  • TABLE 898 SOUTH AMERICA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 480
  • TABLE 899 SOUTH AMERICA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 480
  • TABLE 900 SOUTH AMERICA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 480
  • TABLE 901 SOUTH AMERICA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 481
  • TABLE 902 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 481
  • TABLE 903 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 481
  • TABLE 904 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 482
  • TABLE 905 SOUTH AMERICA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 482
  • TABLE 906 SOUTH AMERICA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 482
  • TABLE 907 SOUTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 482
  • TABLE 908 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 483
  • TABLE 909 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 484
  • TABLE 910 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 484
  • TABLE 911 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 484
  • TABLE 912 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 484
  • TABLE 913 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 485
  • TABLE 914 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 485
  • TABLE 915 BRAZIL CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 485
  • TABLE 916 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 485
  • TABLE 917 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 486
  • TABLE 918 BRAZIL EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 486
  • TABLE 919 BRAZIL KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 486
  • TABLE 920 BRAZIL LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 487
  • TABLE 921 BRAZIL DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 487
  • TABLE 922 BRAZIL MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 487
  • TABLE 923 BRAZIL CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 488
  • TABLE 924 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 488
  • TABLE 925 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 488
  • TABLE 926 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 489
  • TABLE 927 BRAZIL HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 489
  • TABLE 928 BRAZIL DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 489
  • TABLE 929 BRAZIL ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 489
  • TABLE 930 BRAZIL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 490
  • TABLE 931 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 491
  • TABLE 932 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 491
  • TABLE 933 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 491
  • TABLE 934 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 491
  • TABLE 935 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 492
  • TABLE 936 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 492
  • TABLE 937 ARGENTINA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 492
  • TABLE 938 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 492
  • TABLE 939 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 493
  • TABLE 940 ARGENTINA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 493
  • TABLE 941 ARGENTINA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 493
  • TABLE 942 ARGENTINA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 494
  • TABLE 943 ARGENTINA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 494
  • TABLE 944 ARGENTINA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 494
  • TABLE 945 ARGENTINA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 495
  • TABLE 946 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 495
  • TABLE 947 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 495
  • TABLE 948 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 496
  • TABLE 949 ARGENTINA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 496
  • TABLE 950 ARGENTINA DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 496
  • TABLE 951 ARGENTINA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 496
  • TABLE 952 ARGENTINA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 497
  • TABLE 953 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 498
  • TABLE 954 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 498
  • TABLE 955 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 498
  • TABLE 956 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 498
  • TABLE 957 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 499
  • TABLE 958 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 499
  • TABLE 959 PERU CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 ASP (USD) 499
  • TABLE 960 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 499
  • TABLE 961 PERU WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 500
  • TABLE 962 PERU EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 500
  • TABLE 963 PERU KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 500
  • TABLE 964 PERU LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 501
  • TABLE 965 PERU DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 501
  • TABLE 966 PERU MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 501
  • TABLE 967 PERU CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 502
  • TABLE 968 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, GENE TYPE, 2022-2031 (USD THOUSAND) 502
  • TABLE 969 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 502
  • TABLE 970 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 503
  • TABLE 971 PERU HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 503
  • TABLE 972 PERU DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 503
  • TABLE 973 PERU ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2022-2031 (USD THOUSAND) 503
  • TABLE 974 PERU PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 504
  • TABLE 975 REST OF SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 505
  • TABLE 976 SOUTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 VOLUME (UNITS) 506
  • TABLE 977 SOUTH AMERICA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 506

LIST OF FIGURES

  • FIGURE 1 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION 70
  • FIGURE 2 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: DATA TRIANGULATION 73
  • FIGURE 3 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: DROC ANALYSIS 74
  • FIGURE 4 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 75
  • FIGURE 5 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS 75
  • FIGURE 6 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS 76
  • FIGURE 7 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET END USER COVERAGE GRID 78
  • FIGURE 8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: DBMR MARKET POSITION GRID 80
  • FIGURE 9 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS 82
  • FIGURE 10 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION 86
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC E IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET FROM 2024 TO 2031 87
  • FIGURE 12 THE INCREASING ADOPTION OF PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION DEVICES AND PROCEDURES AND RISING PREFERENCE FOR NON-SURGICAL PROCEDURES ARE DRIVING THE GROWTH OF THE GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 88
  • FIGURE 13 ANXIETY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2024 AND 2031 88
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031 89
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET 97
  • FIGURE 16 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PRODUCT, 2023 107
  • FIGURE 17 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PRODUCT, 2024-2031 (USD THOUSAND) 108
  • FIGURE 18 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PRODUCT, CAGR (2024-2031) 108
  • FIGURE 19 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PRODUCT, LIFELINE CURVE 109
  • FIGURE 20 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TEST TYPE, 2023 116
  • FIGURE 21 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TEST TYPE, 2024-2031 (USD THOUSAND) 117
  • FIGURE 22 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TEST TYPE, CAGR (2024-2031) 117
  • FIGURE 23 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TEST TYPE, LIFELINE CURVE 118
  • FIGURE 24 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2023 126
  • FIGURE 25 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2024-2031 (USD THOUSAND) 127
  • FIGURE 26 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2024-2031) 127
  • FIGURE 27 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE 128
  • FIGURE 28 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENE TYPE, 2023 137
  • FIGURE 29 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENE TYPE, 2024-2031 (USD THOUSAND) 138
  • FIGURE 30 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENE TYPE, CAGR (2024-2031) 138
  • FIGURE 31 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENE TYPE, LIFELINE CURVE 139
  • FIGURE 32 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PATIENT TYPE, 2023 153
  • FIGURE 33 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 154
  • FIGURE 34 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PATIENT TYPE, CAGR (2024-2031) 154
  • FIGURE 35 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY PATIENT TYPE, LIFELINE CURVE 155
  • FIGURE 36 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2023 161
  • FIGURE 37 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2024-2031 (USD THOUSAND) 162
  • FIGURE 38 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2024-2031) 162
  • FIGURE 39 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE 163
  • FIGURE 40 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2023 170
  • FIGURE 41 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND) 171
  • FIGURE 42 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 171
  • FIGURE 43 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 172
  • FIGURE 44 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2023) 180
  • FIGURE 45 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2023 (%) 507
  • FIGURE 46 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2023 (%) 508
  • FIGURE 47 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2023 (%) 509
  • FIGURE 48 ASIA-PACIFIC PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2023 (%) 510
目次

The global pharmacogenetics testing in psychiatry/depression market is expected to reach USD 2,664,382.70 thousand by 2031 from USD 1,224,473.84 thousand in 2023, growing with a CAGR of 10.4% in the forecast period of 2024 to 2034.

Market Segmentation

Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing and Chromosomal Array-Based Tests), Patient Type (Child, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software and Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Global Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

  • Driver
  • Rising number of population suffering from depressive disorder
  • Restraint
  • Insufficient clinical validation
  • Opportunity
  • Advancements in genetic testing

Market Players

Some of the major market players operating in the global pharmacogenetics testing in psychiatry/depression market are listed below:

  • ThermoFisher Scientific Inc. (U.S.)
  • Illumina Inc. (U.S.)
  • Myriad Genetics Inc. (U.S.)
  • Sonic Healthcare Limited (Australia)
  • QIAGEN (Germany)
  • AB-BIOTICS S.A. (Spain)
  • BiogeniQ Inc. (Canada)
  • Castle Bioscience Inc. (U.S.)
  • Coriell Life Sciences (U.S.)
  • Dynamic DNA Laboratories (U.S.)
  • Eurofins Scientific (Luxembourg)
  • Genelex (U.S.)
  • Genewiz (U.S.)
  • Genomind Inc. (U.S.)
  • GenXys (Canada)
  • HealthSpek (U.S.)
  • HudsonAlpha (U.S.)
  • MD Labs (U.S.)
  • ONEOME LLC (U.S.)
  • PacBio (U.S.)

TABLE OF CONTENTS

1 INTRODUCTION 62

  • 1.1 OBJECTIVES OF THE STUDY 62
  • 1.2 MARKET DEFINITION 62
  • 1.3 OVERVIEW OF GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 62
  • 1.4 CURRENCY AND PRICING 64
  • 1.5 LIMITATIONS 64
  • 1.6 MARKETS COVERED 65

2 MARKET SEGMENTATION 70

  • 2.1 MARKETS COVERED 70
  • 2.2 GEOGRAPHICAL SCOPE 71
  • 2.3 YEARS CONSIDERED FOR THE STUDY 72
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 73
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 76
  • 2.6 MULTIVARIATE MODELLING 77
  • 2.7 MARKET END USER COVERAGE GRID 78
  • 2.8 TYPE LIFELINE CURVE 79
  • 2.9 DBMR MARKET POSITION GRID 80
  • 2.10 VENDOR SHARE ANALYSIS 82
  • 2.11 SECONDARY SOURCES 83
  • 2.12 ASSUMPTIONS 83

3 EXECUTIVE SUMMARY 84

4 PREMIUM INSIGHT 88

  • 4.1 PESTAL ANALYSIS 90
  • 4.2 PORTERS FIVE FORCES 91

5 INDUSTRIAL INSIGHTS 92

6 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 94

  • 6.1 U.S. 94
  • 6.2 EUROPEAN UNION (EU) 95
  • 6.3 FRANCE 95
  • 6.4 AUSTRALIA 95
  • 6.5 SOUTH KOREA 95

7 MARKET OVERVIEW 96

  • 7.1 DRIVERS 98
    • 7.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER 98
    • 7.1.2 INITIATIVES TAKEN BY MANUFACTURERS DUE TO GENETIC VARIABILITY 98
    • 7.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE 99
    • 7.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION 99
  • 7.2 RESTRAINTS 100
    • 7.2.1 INSUFFICIENT CLINICAL VALIDATION 100
    • 7.2.2 STIGMA AND PERCEPTION FOR MENTAL HEALTH 101
    • 7.2.3 LACK OF REIMBURSEMENT 101
  • 7.3 OPPORTUNITIES 102
    • 7.3.1 ADVANCEMENTS IN GENETIC TESTING 102
    • 7.3.2 EMERGING START-UPS BRANCHES INNOVATION 103
    • 7.3.3 REDUCED HEALTHCARE COSTS THROUGH THE IMPLEMENTATION OF COST-SAVING MEASURES 103
  • 7.4 CHALLENGES 104
    • 7.4.1 RISING CONCERN REGARDING DATA PRIVACY AND SECURITY 104
    • 7.4.2 SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS 105

8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 106

  • 8.1 OVERVIEW 107
  • 8.2 CONSUMABLES 111
  • 8.3 INSTRUMENTS 113
  • 8.4 SOFTWARE AND SERVICES 114

9 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 115

  • 9.1 OVERVIEW 116
  • 9.2 WHOLE GENOME SEQUENCING 119
  • 9.3 CHROMOSOMAL ARRAY BASED TESTS 123

10 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 125

  • 10.1 OVERVIEW 126
  • 10.2 ANXIETY 130
  • 10.3 DEPRESSION 131
  • 10.4 MOOD DISORDERS 132
  • 10.5 BIPOLAR DISORDERS 133
  • 10.6 EATING DISORDERS 134
  • 10.7 PSYCHOTIC DISORDERS 135

11 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 136

  • 11.1 OVERVIEW 137
  • 11.2 CYP2C19 141
  • 11.3 CYP2C9 AND VKORC1 142
  • 11.4 CYP2D6 143
  • 11.5 HLA-B 144
  • 11.6 HTR2A/C 145
  • 11.7 HLA-A 146
  • 11.8 CYP3A4 147
  • 11.9 SLC6A4 148
  • 11.10 MTHFR 149
  • 11.11 COMT 150
  • 11.12 OTHERS 151

12 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 152

  • 12.1 OVERVIEW 153
  • 12.2 ADULT 157
  • 12.3 GERIATRIC 158
  • 12.4 CHILD 159

13 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER 160

  • 13.1 OVERVIEW 161
  • 13.2 HOSPITAL AND CLINICS 164
  • 13.3 DIAGNOSTICS LABORATORIES 166
  • 13.4 ACADEMIC AND RESEARCH INSTITUTES 167
  • 13.5 OTHERS 168

14 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 169

  • 14.1 OVERVIEW 170
  • 14.2 DIRECT TENDER 174
  • 14.3 THIRD PARTY DISTRIBUTION 175
  • 14.4 HOSPITAL PHARMACY 176
  • 14.5 OTHERS 177

15 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 178

  • 15.1 OVERVIEW 179
  • 15.2 NORTH AMERICA 183
    • 15.2.1 U.S. 190
    • 15.2.2 CANADA 197
    • 15.2.3 MEXICO 204
  • 15.3 EUROPE 211
    • 15.3.1 GERMANY 220
    • 15.3.2 FRANCE 228
    • 15.3.3 U.K. 236
    • 15.3.4 ITALY 244
    • 15.3.5 RUSSIA 252
    • 15.3.6 SPAIN 260
    • 15.3.7 TURKEY 268
    • 15.3.8 NETHERLANDS 276
    • 15.3.9 SWITZERLAND 284
    • 15.3.10 POLAND 292
    • 15.3.11 HUNGARY 300
    • 15.3.12 AUSTRIA 308
    • 15.3.13 NORWAY 316
    • 15.3.14 IRELAND 324
    • 15.3.15 LITHUANIA 332
    • 15.3.16 REST OF EUROPE 340
  • 15.4 ASIA-PACIFIC 341
    • 15.4.1 JAPAN 348
    • 15.4.2 CHINA 355
    • 15.4.3 SOUTH KOREA 363
    • 15.4.4 INDIA 371
    • 15.4.5 AUSTRALIA 379
    • 15.4.6 SINGAPORE 387
    • 15.4.7 THAILAND 395
    • 15.4.8 MALAYSIA 403
    • 15.4.9 INDONESIA 411
    • 15.4.10 PHILIPPINES 419
    • 15.4.11 VIETNAM 427
    • 15.4.12 REST OF ASIA-PACIFIC 435
  • 15.5 MIDDLE EAST AND AFRICA 436
    • 15.5.1 SOUTH AFRICA 443
    • 15.5.2 SAUDI ARABIA 450
    • 15.5.3 U.A.E. 456
    • 15.5.4 ISRAEL 462
    • 15.5.5 EGYPT 469
    • 15.5.6 REST OF MIDDLE EAST AND AFRICA 476
  • 15.6 SOUTH AMERICA 477
    • 15.6.1 BRAZIL 484
    • 15.6.2 ARGENTINA 491
    • 15.6.3 PERU 498
    • 15.6.4 REST OF SOUTH AMERICA 505

16 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 507

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL 507
  • 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 508
  • 16.3 COMPANY SHARE ANALYSIS: EUROPE 509
  • 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 510

17 SWOT ANALYSIS 511

18 COMPANY PROFILES 512

  • 18.1 THERMO FISHER SCIENTIFIC INC. 512
    • 18.1.1 COMPANY SNAPSHOT 512
    • 18.1.2 RECENT FINANCIALS 513
    • 18.1.3 COMPANY SHARE ANALYSIS 513
    • 18.1.4 PRODUCT PORTFOLIO 514
    • 18.1.5 RECENT DEVELOPMENT 516
  • 18.2 ILLUMINA, INC. 517
    • 18.2.1 COMPANY SNAPSHOT 517
    • 18.2.2 REVENUE ANALYSIS 517
    • 18.2.3 COMPANY SHARE ANALYSIS 518
    • 18.2.4 PRODUCT PORTFOLIO 518
    • 18.2.5 RECENT DEVELOPMENTS 519
  • 18.3 MYRIAD GENETICS, INC. 520
    • 18.3.1 COMPANY SNAPSHOT 520
    • 18.3.2 REVENUE ANALYSIS 520
    • 18.3.3 COMPANY SHARE ANALYSIS 521
    • 18.3.4 PRODUCT PORTFOLIO 521
    • 18.3.5 RECENT DEVELOPMENTS 522
  • 18.4 SONIC HEALTHCARE LIMITED 523
    • 18.4.1 COMPANY SNAPSHOT 523
    • 18.4.2 REVENUE ANALYSIS 523
    • 18.4.3 COMPANY SHARE ANALYSIS 524
    • 18.4.4 PRODUCT PORTFOLIO 524
    • 18.4.5 RECENT DEVELOPMENT 524
  • 18.5 QIAGEN 525
    • 18.5.1 COMPANY SNAPSHOT 525
    • 18.5.2 REVENUE ANALYSIS 525
    • 18.5.3 COMPANY SHARE ANALYSIS 526
    • 18.5.4 PRODUCT PORTFOLIO 526
    • 18.5.5 RECENT DEVELOPMENTS 527
  • 18.6 AB-BIOTICS, S.A. 529
    • 18.6.1 COMPANY SNAPSHOT 529
    • 18.6.2 PRODUCT PORTFOLIO 529
    • 18.6.3 RECENT DEVELOPMENTS 530
  • 18.7 BIOGENIQ INC. 531
    • 18.7.1 COMPANY SNAPSHOT 531
    • 18.7.2 PRODUCT PORTFOLIO 531
    • 18.7.3 RECENT DEVELOPMENT 532
  • 18.8 CASTLE BIOSCIENCE, INC. 533
    • 18.8.1 COMPANY SNAPSHOT 533
    • 18.8.2 REVENUE ANALYSIS 533
    • 18.8.3 PRODUCT PORTFOLIO 534
    • 18.8.4 RECENT DEVELOPMENTS 534
  • 18.9 CORIELL LIFE SCIENCES 535
    • 18.9.1 COMPANY SNAPSHOT 535
    • 18.9.2 PRODUCT PORTFOLIO 535
    • 18.9.3 RECENT DEVELOPMENTS 535
  • 18.10 DYNAMIC DNA LABORATORIES 537
    • 18.10.1 COMPANY SNAPSHOT 537
    • 18.10.2 PRODUCT PORTFOLIO 537
    • 18.10.3 RECENT DEVELOPMENT 537
  • 18.11 EUROFINS SCIENTIFIC 539
    • 18.11.1 COMPANY SNAPSHOT 539
    • 18.11.2 REVENUE ANALYSIS 540
    • 18.11.3 PRODUCT PORTFOLIO 540
    • 18.11.4 RECENT DEVELOPMENTS 541
  • 18.12 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 542
    • 18.12.1 COMPANY SNAPSHOT 542
    • 18.12.2 REVENUE ANALYSIS 542
    • 18.12.3 PRODUCT PORTFOLIO 543
    • 18.12.4 RECENT DEVELOPMENT 543
  • 18.13 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 544
    • 18.13.1 COMPANY SNAPSHOT 544
    • 18.13.2 REVENUE ANALYSIS 544
    • 18.13.3 PRODUCT PORTFOLIO 545
    • 18.13.4 RECENT DEVELOPMENT 545
  • 18.14 GENOMIND, INC. 546
    • 18.14.1 COMPANY SNAPSHOT 546
    • 18.14.2 PRODUCT PORTFOLIO 546
    • 18.14.3 RECENT DEVELOPMENTS 547
  • 18.15 GENXYS 548
    • 18.15.1 COMPANY SNAPSHOT 548
    • 18.15.2 PRODUCT PORTFOLIO 548
    • 18.15.3 RECENT DEVELOPMENTS 549
  • 18.16 HEALTHSPEK 551
    • 18.16.1 COMPANY SNAPSHOT 551
    • 18.16.2 PRODUCT PORTFOLIO 551
    • 18.16.3 RECENT DEVELOPMENT 551
  • 18.17 HUDSONALPHA 552
    • 18.17.1 COMPANY SNAPSHOT 552
    • 18.17.2 PRODUCT PORTFOLIO 552
    • 18.17.3 RECENT DEVELOPMENT 553
  • 18.18 MD LABS 554
    • 18.18.1 COMPANY SNAPSHOT 554
    • 18.18.2 PRODUCT PORTFOLIO 554
    • 18.18.3 RECENT DEVELOPMENT 554
  • 18.19 ONEOME, LLC 555
    • 18.19.1 COMPANY SNAPSHOT 555
    • 18.19.2 PRODUCT PORTFOLIO 555
    • 18.19.3 RECENT DEVELOPMENTS 556
  • 18.20 PACBIO 558
    • 18.20.1 COMPANY SNAPSHOT 558
    • 18.20.2 REVENUE ANALYSIS 558
    • 18.20.3 PRODUCT PORTFOLIO 559
    • 18.20.4 RECENT DEVELOPMENTS 559

19 QUESTIONNAIRE 561

20 RELATED REPORTS 565